Look back at pharma news to May 5
By Barbara Obstoj-Cardwell. Editor
The big political news last week was that US President Donald Trump finally got the House of Representatives to pass new legislation to repeal and replace The Affordable Care Act, or Obamacare. Also hitting the headlines were Lundbeck and Otsuka’s Rexulti, AstraZeneca’s Imfinzi, a Sosei acquisition, Novartis deal with Celyad, Poxel’s diabetes ambitions and Novo Nordisk results.
The House narrowly passed legislation, the American Health Care Act, in a 217-213 vote, fulfilling a years-long pledge and sending the bill to the Senate. However, according to TheHill, Senate Republicans are signaling they are in no hurry to move legislation to repeal and replace Obamacare after it passed the House Thursday. The House GOP bill is expected to have to undergo significant changes in the upper chamber to meet budgetary rules that would allow it to block a Democratic filibuster.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze